U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C13H16FN3O2
Molecular Weight 265.2834
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of FK-960

SMILES

CC(=O)N1CCN(CC1)NC(=O)C2=CC=C(F)C=C2

InChI

InChIKey=XTOKQKWTUYYVAO-UHFFFAOYSA-N
InChI=1S/C13H16FN3O2/c1-10(18)16-6-8-17(9-7-16)15-13(19)11-2-4-12(14)5-3-11/h2-5H,6-9H2,1H3,(H,15,19)

HIDE SMILES / InChI

Description
Curator's Comment: Description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/11172755 http://adisinsight.springer.com/drugs/800008887

FK-960 [N-(4-acetyl-1-piperazinyl)-p-fluorobenzamide monohydrate], a novel putative anti-dementia drug of piperazine derivative, ameliorates memory deficits in a variety of animal models of dementia in rats and monkeys, and also augments long-term potentiation (LTP) in the mossy fiber-CA3 pathway in guinea-pig hippocampal slices. FK-960 acts as Serotonin modulator. FK-960 had been in phase II clinical trials by Fujisawa Pharmaceutical (now Astellas) for the treatment of Alzheimer's disease (AD). However this study was suspended. In 2003 Phase-II for Alzheimer's disease in USA was discontinued and in Jul 2004 - Phase-II for Cognition disorders in Europe.

CNS Activity

Curator's Comment: After oral administration to rhesus monkeys, FK960 is distributed to the entire brain.

Approval Year

Targets

Targets

Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Unknown

Approved Use

Unknown
Primary
Unknown

Approved Use

Unknown
PubMed

PubMed

TitleDatePubMed
Increase by FK960, a novel cognitive enhancer, in glial cell line-derived neurotrophic factor production in cultured rat astrocytes.
2004 Jul 15
Patents

Sample Use Guides

Rhesus macaques: FK960 was intramuscularly administered at doses of 0, 0.01, 0.1, or 1 mg/kg for seven consecutive days. No statistically significant change in any region was observed at doses of 0.01 or 0.1 mg/kg.
Route of Administration: Intramuscular
FK960 (100nM) increased mRNA and protein levels of glial cell line-derived neurotrophic factor (GDNF) in cultured rat astrocytes.
Name Type Language
FK-960
Code English
BENZAMIDE, N-(4-ACETYL-1-PIPERAZINYL)-4-FLUORO-
Systematic Name English
FK960
Code English
Code System Code Type Description
EPA CompTox
DTXSID50158424
Created by admin on Sat Dec 16 19:10:40 GMT 2023 , Edited by admin on Sat Dec 16 19:10:40 GMT 2023
PRIMARY
FDA UNII
60MMJ100ZX
Created by admin on Sat Dec 16 19:10:40 GMT 2023 , Edited by admin on Sat Dec 16 19:10:40 GMT 2023
PRIMARY
DRUG BANK
DB06465
Created by admin on Sat Dec 16 19:10:40 GMT 2023 , Edited by admin on Sat Dec 16 19:10:40 GMT 2023
PRIMARY
CAS
133920-70-4
Created by admin on Sat Dec 16 19:10:40 GMT 2023 , Edited by admin on Sat Dec 16 19:10:40 GMT 2023
PRIMARY
PUBCHEM
181428
Created by admin on Sat Dec 16 19:10:40 GMT 2023 , Edited by admin on Sat Dec 16 19:10:40 GMT 2023
PRIMARY